Nausicaa Ventures

NGDATA, headquartered in Ghent, Belgium, specializes in consumer intelligence management solutions. The company offers a customer data platform that integrates big data management and machine learning technologies, providing real-time insights and enabling personalized customer experiences. NGDATA serves various industries, including finance, retail, and media, with offices in Belgium, France, Singapore, and the United States.

NGDATA, headquartered in Ghent, Belgium, specializes in consumer intelligence management solutions. The company offers a customer data platform that integrates big data management and machine learning technologies, providing real-time insights and enabling personalized customer experiences. NGDATA serves various industries, including finance, retail, and media, with offices in Belgium, France, Singapore, and the United States.

Ovizio is a company that specializes in digital holographic interferometric microscopy products, particularly focusing on the development of automated systems for cell culture monitoring and analysis. Its innovative technology enables the creation of four-dimensional microscopic imaging devices and accompanying software, specifically designed to assist scientists and biomanufacturers in optimizing and scaling their cell culture processes. By targeting the life sciences bio-processing segment and the research and development market, Ovizio aims to enhance the efficiency and effectiveness of scientific endeavors in these fields.

NGDATA, headquartered in Ghent, Belgium, specializes in consumer intelligence management solutions. The company offers a customer data platform that integrates big data management and machine learning technologies, providing real-time insights and enabling personalized customer experiences. NGDATA serves various industries, including finance, retail, and media, with offices in Belgium, France, Singapore, and the United States.

Bone Therapeutics SA is a biotechnology company based in Gosselies, Belgium, that specializes in the development of innovative cell therapy products for orthopedics and bone diseases. Established in 2006, the company has created a robust product pipeline, including ALLOB, an allogeneic cell therapy currently in Phase II clinical trials aimed at treating delayed-union fractures and spinal fusion procedures. Bone Therapeutics also conducts preclinical research on next-generation products, such as combined cell-matrix therapies for large bone defects and maxillofacial applications. The company collaborates with various partners to develop personalized, tissue-engineered bone implants, leveraging its extensive expertise in bone and joint physiology, along with advanced production methods and minimally invasive treatment techniques.